|
US6297239B1
(en)
|
1997-10-08 |
2001-10-02 |
Merck & Co., Inc. |
Inhibitors of prenyl-protein transferase
|
|
US6566372B1
(en)
|
1999-08-27 |
2003-05-20 |
Ligand Pharmaceuticals Incorporated |
Bicyclic androgen and progesterone receptor modulator compounds and methods
|
|
US6462076B2
(en)
|
2000-06-14 |
2002-10-08 |
Hoffmann-La Roche Inc. |
Beta-amino acid nitrile derivatives as cathepsin K inhibitors
|
|
DE60131423T2
(de)
|
2000-09-08 |
2009-03-19 |
Prozymex A/S |
Ratten-spezifische cathepsin, dipeptidyl peptidase i (dppi): kristallstruktur, hemmstoffe und deren anwendungen
|
|
US20110236367A1
(en)
|
2000-09-08 |
2011-09-29 |
Telenav, Inc. |
Rat cathespin dipeptidyl peptidase i (dppi): crystal structure and its uses
|
|
EP1217000A1
(en)
|
2000-12-23 |
2002-06-26 |
Aventis Pharma Deutschland GmbH |
Inhibitors of factor Xa and factor VIIa
|
|
PL370766A1
(en)
|
2001-12-04 |
2005-05-30 |
F.Hoffmann-La Roche Ag |
Substituted 2-amino-cycloalkanecarboxamides and their use as cysteine protease inhibitors
|
|
US20040253311A1
(en)
|
2002-12-18 |
2004-12-16 |
Roger Berlin |
Multi-layer tablet comprising non-steroidal anti-inflammatory drugs, decongestants and non-sedating antihist amines
|
|
WO2004076434A1
(en)
|
2003-02-28 |
2004-09-10 |
Aic |
Dipeptidyl peptidase inhibitors
|
|
WO2004087153A2
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of organic compounds for immunopotentiation
|
|
WO2004106289A1
(en)
|
2003-05-30 |
2004-12-09 |
Prozymex A/S |
Protease inhibitors
|
|
WO2004110988A1
(en)
|
2003-06-18 |
2004-12-23 |
Prozymex A/S |
Protease inhibitors
|
|
KR101637908B1
(ko)
|
2004-04-07 |
2016-07-11 |
리나트 뉴로사이언스 코프. |
신경성장인자 길항제의 투여에 의한 골암 통증의 치료방법
|
|
EP1745292A2
(en)
|
2004-04-28 |
2007-01-24 |
Bayer HealthCare AG |
Diagnostics and therapeutics for diseases associated with dipeptidyl-peptidase 1 (dpp1)
|
|
US7618981B2
(en)
|
2004-05-06 |
2009-11-17 |
Cytokinetics, Inc. |
Imidazopyridinyl-benzamide anti-cancer agents
|
|
BRPI0508063A
(pt)
|
2004-06-29 |
2007-07-17 |
Nycomed Danmark Aps |
processo para a manufatura de uma composição farmacêutica, nsaid, e, composição farmacêutica
|
|
JP5704785B2
(ja)
|
2004-07-19 |
2015-04-22 |
ザ・ジョンズ・ホプキンス・ユニバーシティ |
免疫抑制のためのｆｌｔ３阻害剤
|
|
CN103169729A
(zh)
|
2005-02-18 |
2013-06-26 |
阿布拉科斯生物科学有限公司 |
治疗剂的组合和给予方式以及联合治疗
|
|
EP1896461A2
(en)
|
2005-06-30 |
2008-03-12 |
Amgen Inc. |
Bis-aryl kinase inhibitors and their use in the treatment of inflammation, angiogenesis and cancer
|
|
AU2008223348A1
(en)
|
2007-03-07 |
2008-09-12 |
Alantos Pharmaceuticals Holding, Inc. |
Metalloprotease inhibitors containing a heterocyclic moiety
|
|
WO2009026701A1
(en)
|
2007-08-29 |
2009-03-05 |
Methylgene Inc. |
Sirtuin inhibitors
|
|
KR20100060004A
(ko)
|
2007-09-25 |
2010-06-04 |
노파르티스 아게 |
에어로졸화된 반코마이신과 같은 의약에 의한 폐 질병의 치료
|
|
US7902181B2
(en)
|
2007-12-12 |
2011-03-08 |
Astrazeneca Ab |
Compounds 010
|
|
US9315449B2
(en)
|
2008-05-15 |
2016-04-19 |
Duke University |
Substituted pyrazoles as heat shock transcription factor activators
|
|
PE20100252A1
(es)
|
2008-06-06 |
2010-04-12 |
Boehringer Ingelheim Int |
Nuevas formulaciones farmaceuticas solidas que comprenden dimaleato de 4-[(3-cloro-4-fluorofenil) amino]-6-{[4-(n,n-dimetilamino)-1-oxo-2-buten-1-il] amino}-7-((s)-tetrahidrofuran-3-iloxi)-quinazolina
|
|
RU2016116516A
(ru)
|
2008-12-08 |
2018-12-07 |
Мандифарма Интернэшнл Корпорейшн Лимитед |
Композиции ингибиторов тирозинкиназных рецепторов белков
|
|
PT2413913T
(pt)
|
2009-04-01 |
2022-06-09 |
Bial Portela & Ca Sa |
Formulações farmacêuticas que compreendem derivados de nitrocatecol e métodos para os preparar
|
|
EA201190235A1
(ru)
|
2009-05-07 |
2012-05-30 |
Астразенека Аб |
Замещенные 1-цианоэтилгетероциклилкарбоксамидные соединения 750
|
|
WO2010142985A1
(en)
|
2009-06-10 |
2010-12-16 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl]piperidin-2-ylcarboxmide compounds 761
|
|
ES2900353T3
(es)
*
|
2010-04-07 |
2022-03-16 |
Vertex Pharma |
Composiciones farmacéuticas de ácido 3-(6-(1-(2,2-difluorobenzo[d][1,3]dioxol-5-il)ciclopropanocarboxamido)-3-metilpiriidin-2-il)benzoico y administración de las mismas
|
|
WO2011154677A1
(en)
|
2010-06-09 |
2011-12-15 |
Astrazeneca Ab |
Substituted n-[1-cyano-2-(phenyl)ethyl] 1-aminocycloalk-1-ylcarboxamide compounds - 760
|
|
WO2012119941A1
(en)
|
2011-03-04 |
2012-09-13 |
Prozymex A/S |
Peptidyl nitrilcompounds as peptidase inhibitors
|
|
US8999975B2
(en)
|
2011-09-19 |
2015-04-07 |
Boehringer Ingelheim International Gmbh |
Substituted N- [1-cyano-2- (phenyl) ethyl] -2-azabicyclo [2.2.1] heptane-3-carboxamide inhibitors of cathepsin C
|
|
JP6479476B2
(ja)
|
2012-02-21 |
2019-03-06 |
メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツングＭｅｒｃｋ Ｐａｔｅｎｔ Ｇｅｓｅｌｌｓｃｈａｆｔ ｍｉｔ ｂｅｓｃｈｒａｅｎｋｔｅｒ Ｈａｆｔｕｎｇ |
ＳｙｋチロシンキナーゼインヒビターおよびＧＣＮ２セリンキナーゼインヒビターとしての８−置換２−アミノー［１，２，４］トリアゾロ［１，５−Ａ］ピラジン類
|
|
CA2870527A1
(en)
|
2012-04-17 |
2013-10-24 |
Astellas Pharma Inc. |
Nitrogenated bicyclic aromatic heterocyclic compound
|
|
WO2014091443A1
(en)
|
2012-12-13 |
2014-06-19 |
Glaxo Group Limited |
Cathepsin c inhibitors for treating cystic fibrosis, non-cystic fibrosis bronchiectasis, and anca-associated vasculitis
|
|
EP2775304A1
(en)
|
2013-03-07 |
2014-09-10 |
Universitätsspital Basel |
Methods for detecting inflammatory disorder
|
|
JP6437929B2
(ja)
|
2013-03-14 |
2018-12-12 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
カテプシンｃの置換二環式１−カルボン酸（ベンジル−シアノ−メチル）−アミド阻害剤
|
|
EA029052B1
(ru)
|
2013-03-14 |
2018-02-28 |
Бёрингер Ингельхайм Интернациональ Гмбх |
Замещенные (бензилцианометил)амиды 2-азабицикло[2.2.1]гептан-3-карбоновых кислот в качестве ингибиторов катепсина с
|
|
EP2970252B1
(en)
|
2013-03-14 |
2020-06-03 |
Boehringer Ingelheim International GmbH |
Substituted 2-aza-bicyclo[2.2.2]octane-3-carboxylic acid (benzyl-cyano-methyl)-amides inhibitors of cathepsin c
|
|
JP6441830B2
(ja)
|
2013-03-14 |
2018-12-19 |
ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング |
カテプシンｃの置換２−アザ−ビシクロ［２．２．１］ヘプタン−３−カルボン酸（シアノ−メチル）−アミド阻害剤
|
|
UY35400A
(es)
|
2013-03-15 |
2014-10-31 |
Novartis Ag |
Compuestos y composiciones para el tratamiento de enfermedades parasitarias
|
|
KR20150135328A
(ko)
|
2013-04-01 |
2015-12-02 |
풀매트릭스 인코퍼레이티드 |
티오트로피움 건조 분말
|
|
WO2015027039A1
(en)
|
2013-08-22 |
2015-02-26 |
Emory University |
Devices and methods related to airway inflammation
|
|
WO2015032942A1
(en)
|
2013-09-09 |
2015-03-12 |
Prozymex A/S |
N-substituted 3,3'-(biphenyl-4,4'-diyl)bis-2-aminopropanenitriles as dppi inhibitors
|
|
CN105612149A
(zh)
|
2013-09-09 |
2016-05-25 |
普罗技迈克斯公司 |
作为二肽基肽酶i抑制剂的肽基腈化合物
|
|
GB201400034D0
(en)
*
|
2014-01-02 |
2014-02-19 |
Astrazeneca Ab |
Pharmaceutical Compositions comprising AZD9291
|
|
NO2699580T3
(enExample)
|
2014-01-24 |
2018-02-24 |
|
|
|
GB201402070D0
(en)
*
|
2014-02-07 |
2014-03-26 |
Galapagos Nv |
Pharmaceutical compositions for the treatment of inflammatory disorders
|
|
CN106456552A
(zh)
*
|
2014-04-10 |
2017-02-22 |
诺华股份有限公司 |
S1p调节剂的立即释放剂量方案
|
|
MX384843B
(es)
|
2014-05-15 |
2025-03-14 |
Insmed Inc |
Métodos para tratar infecciones pulmonares micobacterianas no tuberculosas.
|
|
CN107075557B
(zh)
|
2014-05-30 |
2021-07-06 |
香港大学 |
使用嗜中性粒细胞弹性蛋白酶和蛋白酶3作为诊断生物标志物的方法和组合物
|
|
WO2016016242A1
(en)
|
2014-08-01 |
2016-02-04 |
Boehringer Ingelheim International Gmbh |
Substituted oxetanes and their use as inhibitors of cathepsin c
|
|
HUE047208T2
(hu)
|
2014-09-12 |
2020-04-28 |
Boehringer Ingelheim Int |
A katepszin-C spirociklikus inhibitorai
|
|
MX370366B
(es)
|
2014-11-14 |
2019-12-11 |
Boehringer Ingelheim Int |
Amidas de morfolina y 1,4-oxazepano como agonistas del receptor de somatostatina subtipo 4 (sstr4).
|
|
DK3265452T3
(en)
|
2015-03-05 |
2020-06-08 |
Neuprozyme Therapeutics ApS |
Peptidyl nitril compounds as dipeptidyl peptidase i inhibitors
|
|
WO2018022978A1
(en)
*
|
2016-07-29 |
2018-02-01 |
Insmed Incorporated |
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating bronchiectasis
|
|
EP3749326A4
(en)
|
2018-02-07 |
2021-11-03 |
Insmed Incorporated |
CERTAIN (2S) -N - [(1S) -1-CYANO-2-PHENYLETHYL] -1,4-OXAZEPAN-2-CARBOXAMIDE FOR THE TREATMENT OF VASCULITIDES ASSOCIATED WITH ANCA
|
|
PT3758708T
(pt)
|
2018-03-01 |
2025-02-13 |
Astrazeneca Ab |
Composições farmacêuticas compreendendo (2s)-{(1,s)-1-ciano-2-[4-(3-metil-2-oxo-2,3-di-hidro-1,3-benzoxazol-5-il)fenil]etil}-1,4-oxazepano-2-carboxamida
|
|
WO2020018551A1
(en)
|
2018-07-17 |
2020-01-23 |
Insmed Incorporated |
Certain (2s)- n-[(1s)-1-cyano-2-phenylethyl]-1,4- oxazepane-2-carboxamides for treating inflammatory bowel disease
|
|
CA3106269A1
(en)
|
2018-07-17 |
2020-01-23 |
Insmed Incorporated |
Certain (2s)-n-[(1s)-1-cyano-2-phenylethyl]-1,4-oxazepane-2-carboxamides for treating lupus nephritis
|
|
EP4252844A3
(en)
|
2019-04-17 |
2023-12-06 |
Azora Therapeutics, Inc. |
Topical compositions and methods for treating inflammatory skin diseases
|
|
AU2020289560A1
(en)
|
2019-06-05 |
2021-12-23 |
Emory University |
Peptidomimetics for the treatment of coronavirus and picornavirus infections
|
|
WO2022140516A1
(en)
|
2020-12-22 |
2022-06-30 |
Insmed Incorporated |
Certain (25)-iv-[(ls')~ i-c yan0-2-phenylethyl·]- 1,4-oxazepane-2- carboxamides for treating behcet's disease
|
|
CN112920124B
(zh)
|
2021-01-29 |
2024-03-01 |
安徽医科大学 |
一种嘧啶-2,4-二胺类化合物及其制备方法与应用
|
|
WO2022232420A1
(en)
|
2021-04-29 |
2022-11-03 |
Insmed Incorporated |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cancer
|
|
US20240226112A1
(en)
|
2021-04-29 |
2024-07-11 |
Insmed Incorporated |
Certain n-(1-cyano-2-phenylethyl)-1,4-oxazepane-2-carboxamides for treating cystic fibrosis
|
|
CN118159525A
(zh)
|
2021-10-29 |
2024-06-07 |
英斯梅德股份有限公司 |
用于治疗慢性鼻窦炎的特定n-(1-氰基-2-苯乙基)-1,4-氧杂氮杂环庚烷-2-甲酰胺
|
|
JP2025508359A
(ja)
|
2022-02-16 |
2025-03-26 |
インスメッド インコーポレイテッド |
化膿性汗腺炎を治療するためのある特定のｎ－（１－シアノ－２－フェニルエチル）－１，４－オキサゼパン－２－カルボキサミド
|